Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms

Sangeeta Nischal, Sanchari Bhattacharyya, Maximilian Christopeit, Yiting Yu, Li Zhou, Tushar D. Bhagat, Davendra Sohal, Britta Will, Yongkai Mo, Masako Suzuki, Animesh Pardanani, McDevitt Michael McDevitt, Jaroslaw P. Maciejewski, Ari M. Melnick, John M. Greally, Ulrich G. Steidl, Alison Moliterno, Amit K. Verma

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Even though mutations in epigenetic regulators frequently occur in myeloproliferative neoplasms, their effects on the epigenome have not been well studied. Furthermore, even though primary myelofibrosis (PMF) has a markedly worse prognosis than essential thrombocytosis or polycythemia vera, the molecular distinctions between these subgroups are not well elucidated. We conducted the HELP (HpaII tiny fragment enriched by LM-PCR) assay to study genome-wide methylation in polycythemia vera, essential thrombocytosis, and PMF samples compared with healthy controls. We determined that polycythemia vera and essential thrombocytosis are characterized by aberrant promoter hypermethylation, whereas PMF is an epigenetically distinct subgroup characterized by both aberrant hyper- and hypomethylation. Aberrant hypomethylation in PMF was seen to occur in non-CpG island loci, showing further qualitative differences between the disease subgroups. The differentially methylated genes in polycythemia vera and essential thrombocytosis were involved predominantly in cell signaling pathways and were enriched for binding sites of GATA1 and other transcription factors. In contrast, aberrantly methylated genes in PMF were involved in inflammatory pathways and were enriched for NF1, LEF1, and other transcription factors. Within the PMF subgroup, cases with ASXL1 disruptions formed an epigenetically distinct subgroup with relatively increased methylation. Cases of myeloproliferative neoplasms (MPN) with TET2 mutations showed decreased levels of hydroxymethylation and distinct set of hypermethylated genes. In contrast, the JAK2V617F mutation did not drive epigenetic clustering within MPNs. Finally, the significance of aberrant methylation was shown by sensitivity of MPN-derived cell lines to decitabine. These results show epigenetic differences between PMF and polycythemia vera/essential thrombocytosis and reveal methylomic signatures of ASXL1 and TET2 mutations.

Original languageEnglish (US)
Pages (from-to)1076-1085
Number of pages10
JournalCancer Research
Volume73
Issue number3
DOIs
StatePublished - Feb 1 2013

Fingerprint

Primary Myelofibrosis
Polycythemia Vera
Thrombocytosis
Neoplasms
Epigenomics
Methylation
Mutation
decitabine
GATA1 Transcription Factor
Genes
Islands
Cluster Analysis
Transcription Factors
Binding Sites
Genome
Cell Line
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. / Nischal, Sangeeta; Bhattacharyya, Sanchari; Christopeit, Maximilian; Yu, Yiting; Zhou, Li; Bhagat, Tushar D.; Sohal, Davendra; Will, Britta; Mo, Yongkai; Suzuki, Masako; Pardanani, Animesh; Michael McDevitt, McDevitt; Maciejewski, Jaroslaw P.; Melnick, Ari M.; Greally, John M.; Steidl, Ulrich G.; Moliterno, Alison; Verma, Amit K.

In: Cancer Research, Vol. 73, No. 3, 01.02.2013, p. 1076-1085.

Research output: Contribution to journalArticle

Nischal, S, Bhattacharyya, S, Christopeit, M, Yu, Y, Zhou, L, Bhagat, TD, Sohal, D, Will, B, Mo, Y, Suzuki, M, Pardanani, A, Michael McDevitt, M, Maciejewski, JP, Melnick, AM, Greally, JM, Steidl, UG, Moliterno, A & Verma, AK 2013, 'Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms', Cancer Research, vol. 73, no. 3, pp. 1076-1085. https://doi.org/10.1158/0008-5472.CAN-12-0735
Nischal, Sangeeta ; Bhattacharyya, Sanchari ; Christopeit, Maximilian ; Yu, Yiting ; Zhou, Li ; Bhagat, Tushar D. ; Sohal, Davendra ; Will, Britta ; Mo, Yongkai ; Suzuki, Masako ; Pardanani, Animesh ; Michael McDevitt, McDevitt ; Maciejewski, Jaroslaw P. ; Melnick, Ari M. ; Greally, John M. ; Steidl, Ulrich G. ; Moliterno, Alison ; Verma, Amit K. / Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. In: Cancer Research. 2013 ; Vol. 73, No. 3. pp. 1076-1085.
@article{87c5ee2fa5254eb59db7dacdc3db32fe,
title = "Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms",
abstract = "Even though mutations in epigenetic regulators frequently occur in myeloproliferative neoplasms, their effects on the epigenome have not been well studied. Furthermore, even though primary myelofibrosis (PMF) has a markedly worse prognosis than essential thrombocytosis or polycythemia vera, the molecular distinctions between these subgroups are not well elucidated. We conducted the HELP (HpaII tiny fragment enriched by LM-PCR) assay to study genome-wide methylation in polycythemia vera, essential thrombocytosis, and PMF samples compared with healthy controls. We determined that polycythemia vera and essential thrombocytosis are characterized by aberrant promoter hypermethylation, whereas PMF is an epigenetically distinct subgroup characterized by both aberrant hyper- and hypomethylation. Aberrant hypomethylation in PMF was seen to occur in non-CpG island loci, showing further qualitative differences between the disease subgroups. The differentially methylated genes in polycythemia vera and essential thrombocytosis were involved predominantly in cell signaling pathways and were enriched for binding sites of GATA1 and other transcription factors. In contrast, aberrantly methylated genes in PMF were involved in inflammatory pathways and were enriched for NF1, LEF1, and other transcription factors. Within the PMF subgroup, cases with ASXL1 disruptions formed an epigenetically distinct subgroup with relatively increased methylation. Cases of myeloproliferative neoplasms (MPN) with TET2 mutations showed decreased levels of hydroxymethylation and distinct set of hypermethylated genes. In contrast, the JAK2V617F mutation did not drive epigenetic clustering within MPNs. Finally, the significance of aberrant methylation was shown by sensitivity of MPN-derived cell lines to decitabine. These results show epigenetic differences between PMF and polycythemia vera/essential thrombocytosis and reveal methylomic signatures of ASXL1 and TET2 mutations.",
author = "Sangeeta Nischal and Sanchari Bhattacharyya and Maximilian Christopeit and Yiting Yu and Li Zhou and Bhagat, {Tushar D.} and Davendra Sohal and Britta Will and Yongkai Mo and Masako Suzuki and Animesh Pardanani and {Michael McDevitt}, McDevitt and Maciejewski, {Jaroslaw P.} and Melnick, {Ari M.} and Greally, {John M.} and Steidl, {Ulrich G.} and Alison Moliterno and Verma, {Amit K.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-12-0735",
language = "English (US)",
volume = "73",
pages = "1076--1085",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms

AU - Nischal, Sangeeta

AU - Bhattacharyya, Sanchari

AU - Christopeit, Maximilian

AU - Yu, Yiting

AU - Zhou, Li

AU - Bhagat, Tushar D.

AU - Sohal, Davendra

AU - Will, Britta

AU - Mo, Yongkai

AU - Suzuki, Masako

AU - Pardanani, Animesh

AU - Michael McDevitt, McDevitt

AU - Maciejewski, Jaroslaw P.

AU - Melnick, Ari M.

AU - Greally, John M.

AU - Steidl, Ulrich G.

AU - Moliterno, Alison

AU - Verma, Amit K.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Even though mutations in epigenetic regulators frequently occur in myeloproliferative neoplasms, their effects on the epigenome have not been well studied. Furthermore, even though primary myelofibrosis (PMF) has a markedly worse prognosis than essential thrombocytosis or polycythemia vera, the molecular distinctions between these subgroups are not well elucidated. We conducted the HELP (HpaII tiny fragment enriched by LM-PCR) assay to study genome-wide methylation in polycythemia vera, essential thrombocytosis, and PMF samples compared with healthy controls. We determined that polycythemia vera and essential thrombocytosis are characterized by aberrant promoter hypermethylation, whereas PMF is an epigenetically distinct subgroup characterized by both aberrant hyper- and hypomethylation. Aberrant hypomethylation in PMF was seen to occur in non-CpG island loci, showing further qualitative differences between the disease subgroups. The differentially methylated genes in polycythemia vera and essential thrombocytosis were involved predominantly in cell signaling pathways and were enriched for binding sites of GATA1 and other transcription factors. In contrast, aberrantly methylated genes in PMF were involved in inflammatory pathways and were enriched for NF1, LEF1, and other transcription factors. Within the PMF subgroup, cases with ASXL1 disruptions formed an epigenetically distinct subgroup with relatively increased methylation. Cases of myeloproliferative neoplasms (MPN) with TET2 mutations showed decreased levels of hydroxymethylation and distinct set of hypermethylated genes. In contrast, the JAK2V617F mutation did not drive epigenetic clustering within MPNs. Finally, the significance of aberrant methylation was shown by sensitivity of MPN-derived cell lines to decitabine. These results show epigenetic differences between PMF and polycythemia vera/essential thrombocytosis and reveal methylomic signatures of ASXL1 and TET2 mutations.

AB - Even though mutations in epigenetic regulators frequently occur in myeloproliferative neoplasms, their effects on the epigenome have not been well studied. Furthermore, even though primary myelofibrosis (PMF) has a markedly worse prognosis than essential thrombocytosis or polycythemia vera, the molecular distinctions between these subgroups are not well elucidated. We conducted the HELP (HpaII tiny fragment enriched by LM-PCR) assay to study genome-wide methylation in polycythemia vera, essential thrombocytosis, and PMF samples compared with healthy controls. We determined that polycythemia vera and essential thrombocytosis are characterized by aberrant promoter hypermethylation, whereas PMF is an epigenetically distinct subgroup characterized by both aberrant hyper- and hypomethylation. Aberrant hypomethylation in PMF was seen to occur in non-CpG island loci, showing further qualitative differences between the disease subgroups. The differentially methylated genes in polycythemia vera and essential thrombocytosis were involved predominantly in cell signaling pathways and were enriched for binding sites of GATA1 and other transcription factors. In contrast, aberrantly methylated genes in PMF were involved in inflammatory pathways and were enriched for NF1, LEF1, and other transcription factors. Within the PMF subgroup, cases with ASXL1 disruptions formed an epigenetically distinct subgroup with relatively increased methylation. Cases of myeloproliferative neoplasms (MPN) with TET2 mutations showed decreased levels of hydroxymethylation and distinct set of hypermethylated genes. In contrast, the JAK2V617F mutation did not drive epigenetic clustering within MPNs. Finally, the significance of aberrant methylation was shown by sensitivity of MPN-derived cell lines to decitabine. These results show epigenetic differences between PMF and polycythemia vera/essential thrombocytosis and reveal methylomic signatures of ASXL1 and TET2 mutations.

UR - http://www.scopus.com/inward/record.url?scp=84873454471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873454471&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0735

DO - 10.1158/0008-5472.CAN-12-0735

M3 - Article

C2 - 23066032

AN - SCOPUS:84873454471

VL - 73

SP - 1076

EP - 1085

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 3

ER -